欧美午夜精品久久久久免费视-亚洲国产精品无码久久久-鲁鲁狠狠狠7777一区二区-特黄aaaaaaa片免费视频

Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Isoxazole, 5-Methyl-3,4-diphenyl(Parecoxib Sodium intermediate) is an organic compound that serves as a key intermediate in the synthesis of Parecoxib Sodium, a selective COX-2 inhibitor developed by Pfizer. It plays a crucial role in the pharmaceutical industry due to its involvement in the production of medications aimed at alleviating pain and inflammation.

37928-17-9 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 37928-17-9 Structure
  • Basic information

    1. Product Name: Isoxazole, 5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate)
    2. Synonyms: Isoxazole, 5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate);Isoxazole, 5-Methyl-3,4-diphenyl-;3,4-Diphenyl-5-methylisoxazole;5-Methyl-3,4-diphenylisoxazole;3-Phenyl-4-(4-aMinosulfonylbenzyl)-5-Methylisoxazole,Valdecoxib IMpurity A;Parecoxib SodiuM interMediate A;Parecoxib InterMediate (5-Mehyl-3,4-Diphenylisoxazole);5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate)
    3. CAS NO:37928-17-9
    4. Molecular Formula: C16H13NO
    5. Molecular Weight: 235.28052
    6. EINECS: 1592732-453-0
    7. Product Categories: API
    8. Mol File: 37928-17-9.mol
  • Chemical Properties

    1. Melting Point: 96.0 to 100.0 °C
    2. Boiling Point: 340.1±21.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.108±0.06 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: Sealed in dry,Room Temperature
    8. Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
    9. PKA: -2.53±0.50(Predicted)
    10. CAS DataBase Reference: Isoxazole, 5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate)(CAS DataBase Reference)
    11. NIST Chemistry Reference: Isoxazole, 5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate)(37928-17-9)
    12. EPA Substance Registry System: Isoxazole, 5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate)(37928-17-9)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 37928-17-9(Hazardous Substances Data)

37928-17-9 Usage

Uses

Used in Pharmaceutical Industry:
Isoxazole, 5-Methyl-3,4-diphenyl(Parecoxib Sodium intermediate) is used as a key intermediate for the synthesis of Parecoxib Sodium, a COX-2 inhibitor, for the short-term therapy of postoperative pain. Its role in the development of Parecoxib Sodium, which was listed in the European Union in 2002 under the trade name Dynastat, highlights its importance in providing relief for patients recovering from surgery.
Additionally, Isoxazole, 5-Methyl-3,4-diphenyl(Parecoxib Sodium intermediate) is used as a reagent for the preparation of valdecoxib and its analogues. Valdecoxib is another COX-2 inhibitor that has been utilized for the treatment of pain and inflammation, further emphasizing the compound's significance in the pharmaceutical sector.

Synthesis

In four mouthfuls of round-bottomed flasks of a 1L add compound 2 (40g), methanol (400mL), 7.7% Aqueous sodium carbonate (400mL), is heated to 70 DEG C, after stirring reaction 2h, and TLC plate monitoring raw material Fundamental reaction is complete, and solution is divided into solid-liquid biphase, is extracted with ethyl acetate, collected organic layer, with anhydrous Sodium sulfate is dried, and vacuum obtains white solid, HPLC purity: 94.9% after being spin-dried for.White solid uses 40ml ethyl acetate and the mixed solvent recrystallization of 120ml normal hexane (1:3) again, Obtaining target compound is white solid 34.2g, yield 92%, HPLC purity: 99.7%.m.p.97-98℃; MS(m/z):236(M+H)+;1H NMR(400MHz,CDCl3) δ:2.43(s,3H,-CH3), 7.19-7.43 (m, 10H ,-CH=).

Check Digit Verification of cas no

The CAS Registry Mumber 37928-17-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,9,2 and 8 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 37928-17:
(7*3)+(6*7)+(5*9)+(4*2)+(3*8)+(2*1)+(1*7)=149
149 % 10 = 9
So 37928-17-9 is a valid CAS Registry Number.

37928-17-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-Methyl-3,4-diphenylisoxazole

1.2 Other means of identification

Product number -
Other names 5-Methyl-3,4-diphenyl-1,2-oxazole

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:37928-17-9 SDS

37928-17-9Relevant articles and documents

NHC-palladium-catalyzed ionic liquid-accelerated regioselective oxyarylation of alkynes with diaryl ethers?

Cen, Liying,He, Dan,Jiang, Huanfeng,Li, Jianxiao,Lin, Zidong,Wu, Wanqing

supporting information, p. 1983 - 1988 (2022/04/03)

The first NHC-palladium-catalyzed regioselective oxyarylation of oxime ether in a task-specific ionic liquid via C(sp3)-O and C(sp2)-O bond cleavage of two different types of ethers for the assembly of structurally diverse 4-arylisoxazoles is described. Both the basic ionic liquid [C3NH2mim]Br and NHC-Pd catalyst IPr-Pd-Im-Cl2 played an important role in this transformation. Notably, this new approach provides a practical and straightforward route to access a broad range of privileged 4-arylisoxazole structures with good yields and excellent regioselectivities. Significantly, this catalytic system can be recycled up to eight times without significant loss of catalytic activity.

Preparation method of parecoxib sodium intermediate 5-methyl-3,4-diphenyl isoxazole

-

, (2018/07/06)

The invention relates to a preparation method of parecoxib sodium intermediate 5-methyl-3,4-diphenyl isoxazole. The preparation method comprises the following steps: step one, taking phenyl propinyl ketone as a starting material, firstly, carrying out condensation with methanol aminated hydrochloride to generate Z-type 1-phenyl-1-propinyl-3-methyl-oxime; step two, carrying out a cycloaddition reaction on the Z-type 1-phenyl-1-propinyl-3-methyl-oxime and iodine chloride to generate 3-phenyl-4-iodo-5-methyl isoxazole; and step three, carrying out a substitution reaction on the 3-phenyl-4-iodo-5-methyl isoxazole and phenylboronic acid to generate 5-methyl-3,4-diphenyl isoxazole.

Highly Site Selective Formal [5+2] and [4+2] Annulations of Isoxazoles with Heterosubstituted Alkynes by Platinum Catalysis: Rapid Access to Functionalized 1,3-Oxazepines and 2,5-Dihydropyridines

Shen, Wen-Bo,Xiao, Xin-Yu,Sun, Qing,Zhou, Bo,Zhu, Xin-Qi,Yan, Juan-Zhu,Lu, Xin,Ye, Long-Wu

supporting information, p. 605 - 609 (2017/01/07)

Platinum-catalyzed formal [5+2] and [4+2] annulations of isoxazoles with heterosubstituted alkynes enabled the atom-economical synthesis of valuable 1,3-oxazepines and 2,5-dihydropyridines, respectively. Importantly, this Pt catalysis not only led to unique reactivity dramatically divergent from that observed under Au catalysis, but also proceeded via unprecedented α-imino platinum carbene intermediates.

Method for preparing parecoxib sodium key intermediates

-

, (2017/08/29)

The invention relates to a method for preparing parecoxib sodium key intermediates, and belongs to the field of medicine synthesis. The method for preparing the parecoxib sodium key intermediates includes steps of firstly, preparing 1-(1-methyl-2-styrene)-pyrrolidine (a compound I); secondly, preparing 5-methyl-3, 4-diphenyl-5-(pyrrolidine-1-base)-4, 5-dihydro-isoxazole (a compound II); thirdly, preparing a crude product of 5-methyl-3, 4-diphenyl isoxazole (a compound III); fourthly, refining a crude product of 5-methyl-3, 4-diphenyl-5-isoxazole (a compound III). The shortcomings of existing synthesis methods can be overcome by the aid of the method. The method for preparing the parecoxib sodium key intermediates has the advantages of mild reaction conditions, inexpensive and easily available raw materials, simplicity in after-treatment operation, short production cycle and high product purity and yield. Besides, the novel method is provided for preparing the parecoxib sodium key intermediates.

Preparation method of 5-methyl-3,4-diphenylisoxazole

-

Paragraph 0027; 0028; 0029; 0030; 0031; 0032; 0033-0040, (2017/07/20)

The invention discloses a preparation method of 5-methyl-3,4-diphenylisoxazole, which includes a step of performing a dehydration reaction to a compound (2) in methanol and water in the presence of an inorganic alkali to prepare the 5-methyl-3,4-diphenylisoxazole.

Method for preparing parecoxib for treating postoperative pain

-

Paragraph 0005; 0059; 0060; 0061, (2017/01/12)

The invention discloses a method for preparing parecoxib for treating postoperative pain. The method comprises the following steps: 1) conducting a contact reaction between 3,4-diphenyl-4-(1-pyrrolidyl)-3-butene-2-one and ammonium acetate in acetic acid; after the reaction, diluting dichloromethane; regulating the pH value to 6-7 with saturated sodium bicarbonate; concentrating the organic phase and washing; recrystallizing with ethanol; and drying to obtain 5-methyl-3,4-diphenyl isoxazole; 2) stirring the obtained 5-methyl-3,4-diphenyl isoxazole and chlorosulfonic acid for reacting; adding anion exchange resin, and dropwise adding saturated ammonium chloride and dichloromethane for extraction; washing and concentrating; and recrystallizing with ethanol to obtain valdecoxib; and 3) enabling the valdecoxib obtained in the step 2) to react with propionic anhydride in the presence of triethylamine to obtain parecoxib. The method for preparing parecoxib, disclosed by the invention, has the advantages of simple steps, mild conditions and high yield.

A process for the preparation of sodium compound handkerchief auspicious past cloth and wherein the intermediate impurity, preparation method and application

-

Paragraph 0085; 0086, (2017/02/24)

The invention provides parecoxib sodium which is prepared by controlling an intermediate impurity and in particular provides a preparation method of a parecoxib sodium compound as well as the intermediate impurity and an application of the parecoxib sodium compound. According to the preparation method provided by the invention, 3-methyl-4,5-diphenyl-4,5-dihydro-isoxazole-5-alcohol is used as an isomer impurity for preparing 5-methyl-3,4-diphenyl-4,5-dihydro-isoxazole-5-alcohol as an intermediate of the parecoxib sodium, the quality of the 3-methyl-4,5-diphenyl-4,5-dihydro-isoxazole-5-alcohol is controlled in the preparation of the parecoxib sodium, specifically, the impurity content is required not to be higher than 0.5 percent, and an important significance is provided for the product quality of the parecoxib sodium; by obtaining the 3-methyl-4,5-diphenyl-4,5-dihydro-isoxazole-5-alcohol as an isomer impurity of the important 5-methyl-3,4-diphenyl-4,5-dihydro-isoxazole-5-alcohol and further studying 3-methyl-4,5-diphenyl-4,5-dihydro-isoxazole-5-alcohol in the aspects of preparation process, detection process and purification process, important quality monitoring significance is provided for the process with the 5-methyl-3,4-diphenyl-4,5-dihydro-isoxazole-5-alcohol as an industrial production raw material.

Method for preparing parecoxib intermediate

-

Paragraph 0016; 0021; 0022; 0023; 0025; 0027; 0029-0041, (2018/02/03)

The invention discloses a method for preparing a parecoxib intermediate. The method includes subjecting 1, 2-diphenyl-2-acetyl ethyl ketone and ammonium acetate to contact reaction with the presence of iodobenzene diacetate and potassium iodide, performing organic-phase concentration and washing after reaction, performing ethyl alcohol recrystallization, and drying to obtain 5-methyl-3, 4-diphenyl isoxazole. The method for preparing the parecoxib intermediate has the advantages of simplicity in procedure and high yield.

A method of preparing intermediates handkerchief auspicious past cloth sodium

-

Paragraph 0029; 0030; 0031, (2017/05/05)

The invention discloses a novel method for preparing a parecoxib sodium intermediate 5-methyl-3, 4-diphenyl isoxazole. The method comprises the following steps: performing rearrangement reaction on a compound in the formula I (referring to the Specification)under the action of a catalyst to prepare a compound in the formula II(referring to the Specification); and under the condition of a catalyst, reacting hydroxylammonium chloride with the compound in the formula II to prepare 5-methyl-3,4-diphenyl isoxazole. The method disclosed by the invention has the advantages of mild reaction condition, good simplicity and convenience for operation, low cost, environmental-friendliness and the like.

Preparation method of cyclooxygenase-2 inhibitor parecoxib

-

Paragraph 0027; 0028; 0029, (2016/11/14)

The invention discloses a preparation method of a cyclooxygenase-2 inhibitor parecoxib. The method comprises the following steps that 1, benzaldoxime reacts with 1-phenylpropyne in the presence of tris(2-phenylpyridine)iridium (III), triethylamine and magnesium oxide under the illumination condition to obtain 5-methyl-3,4-diphenylisoxazole; 2, a stirring reaction is conducted on 5-methyl-3,4-diphenylisoxazole obtained in the first step and chlorosulfonic acid, dichloromethane extraction is conducted after the reaction is completed, a dichloromethane phase is directly added into ammonium hydroxide, an organic phase is separated, water washing, concentrating and ethanol recrystallization are conducted, and valdecoxib is obtained; 3, valdecoxib obtained in the second step reacts with propionic anhydride in the presence of triethylamine, and parecoxib is obtained. The preparation method of parecoxib is simple in step, high in yield and simple in posttreatment.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 37928-17-9